Pacira Pharma (PCRX) Tops Q2 EPS by 16c

Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.19, $0.16 better than the analyst estimate of $0.03. Revenue for the quarter came in at $69.6 million versus the consensus estimate of $67.8 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• Ackman adds Netflix, Visa and Mastercard in portfolio revamp
• Bragg Gaming Group Inc. (BRAG) Tops Q2 EPS by 2c
• Forum Markets, Incorporated (FRMM) Tops Q2 EPS by 29c ; Offers Guidance